Skip to main content
Equibles
ANIX logo

ANIX · Anixa Biosciences Inc

Track ANIX — free

Use ANIX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANIX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.76 +0.01 (+0.36%) At close · Sep 11
Rebalance outlook locked
Market Cap
$96.47M
Shares
34.76M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.76 Open$2.87 Day$2.72–2.88 52W close$2.35–5.22 Avg vol 30d273K Short int993K · 2.9% float · 3.3d Short vol81% DataJan 2020–Sep 2026 Filing10-Q · Sep 9

Up next

Latest filing: 10-Q
filed Sep 9, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$10.38M
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
-6,586.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.3%
Year over year · more shares
Price change (1Y)
-8.9%
Trailing year
Short interest
2.9%
Latest settlement · 3.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −12%
below
Price vs 50-day avg −17%
below
RSI (14) 30
oversold
MACD trend Negative
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −14%
trailing
6-month return +4%
trailing
YTD return −12%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +9 funds added
Insider flow Accumulating
Net +$161.1K over 90 days · 0% sells
Short interest Rising
2.86% of float · ▲ +1.6% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
64 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Strong
Revenue growth 0%
Y/Y
EPS growth +13%
Y/Y
Free cash flow $-7.2M
Balance sheet $4.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −55%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−12% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
30 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +9 funds added
Insider flow Accumulating
Net +$161.1K over 90 days · 0% sells
Short interest Rising
2.86% of float · ▲ +1.6% MoM · 3.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
64 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $3 · 14% Range high $5
vs 200-day avg -12% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANIX
Anixa Biosciences Inc
this stock
$96.47M -11.5% +0.0% — 2.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
64
% held
15.5%
Net QoQ
+233.7K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
12
View
Short & Settlement
Short Interest Rising
Shares short
993.2K
Days to cover
3.3d
Change
+15.2K sh
View
Short Volume
Short vol %
81%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$5.1K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
53.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$161.1K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$210.0K
Net income (FY)
$-10.9M
EPS diluted
$-0.34
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 11, 2026
This year
8
View
Earnings & Events
Earnings Calls
Last call
Sep 11, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ANIX -9.5% -13.8% +4.2% -17.6% -11.5%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -8.4% -12.0% -13.7% -17.3% -23.6%
Key facts CIK 715446 CUSIP 03528H109 13F (30d) 29 filings 29 filers Visit website Investor relations